Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the American Society of Hematology and the Society of Urologic Oncology Annual Meetings

SEATTLE, Dec. 3, 2010 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following PROVENGE® (sipuleucel-T) data presentations taking place at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida and the Society of Urologic Oncology (SUO) Annual Meeting in Bethesda, Maryland.

The following data presentations will take place at the ASH Annual Meeting on Saturday, December 4, 2010, at 5:30 p.m. ET:

  • A poster titled, "Elevated Eosinophils Following Treatment with Sipuleucel-T in Men with Prostate Cancer is Associated with Antigen-Specific Immune Response and Prolonged Survival (abstract #1491)," presented by Robert Sims, M.D., senior medical director of clinical affairs of Dendreon.
  • A poster titled, "Increased Gamma Globulin Following Immunotherapy with Sipuleucel-T is Associated with Antigen-Specific Antibody Responses (abstract #1738)," presented by Dr. Sims.

The following data presentation will take place at the SUO Annual Meeting on Thursday, December 9, 2010, at 4:00 p.m. ET:

  • A poster titled, "Sipuleucel-T Immunotherapy for Advanced Prostate Cancer; Integrated Results from Randomized, Double-Blind, Controlled Trials (abstract #22)," presented by Allan Pantuck, M.D., associate professor of urology at the University of California, Los Angeles.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including progress on the commercialization efforts for PROVENGE.  Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Webcast Presentation at Credit Suisse 2010 Health Care Conference
2. Dendreon Reports Third Quarter 2010 Financial Results
3. Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
4. Dendreon Statement on CMS National Coverage Analysis
5. Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting
6. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
7. Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
8. Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
9. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
10. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... ScanWise Implant, the industry,s first MRI guided user interface ... scanning of patients with MR Conditional implants, such as ... the 2015 Radiological Society of North America Annual ... exams and supports diagnostic confidence of this growing patient ...
(Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
(Date:11/30/2015)... PUNE, India , November 30, 2015 ... new market research report "Dental Lasers Market by Product (Soft ... Treatment, Periodontitis), End User (Hospitals, Clinics), and Geography - Global ... USD 224.7 Million by 2020, at a CAGR of 5.2% ... , Browse 140 market data Tables and 62 Figures spread ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... December 01, 2015 , ... ... Colon as a 2015-2016 inductee into its VIP Woman of the Year ... is the nation’s leading networking organization exclusively for professional women, boasting 850,000 members ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National ... 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized ... networking organization exclusively for professional women, boasting 850,000 members and over 200 operating ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live Very Well is ... insurance plans on . The multi-carrier insurance exchange platform offers individual ... allowing consumers to compare, quote and match plans to meet their needs. ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Until now, ... criteria set forth in the MOMS (Management of Myelomeningocele Study) trial. One of these ... Control and Prevention), a BMI of 18.5 to 24.9 is considered normal, 25 - ...
(Date:11/30/2015)... ... 2015 , ... Stress, anxiety, illness, infection or even a need for eyeglasses ... Heather Spader, MD, a new pediatric neurosurgeon at Joe DiMaggio Children’s Hospital in Hollywood, ... tumors. , “Bad headaches that don’t go away, that don’t have any ...
Breaking Medicine News(10 mins):